Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Keytruda = $265,000 (17 doses per year)
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(548)
•••
Comment by Rumpl3StiltSkinon Apr 14, 2023 11:10am
135 Views
Post# 35395196

RE:RE:RE:RE:RE:RE:Keytruda = $265,000 (17 doses per year)

RE:RE:RE:RE:RE:RE:Keytruda = $265,000 (17 doses per year)I think that it might be more that 2 weeks poop. hope I'm wrong. But yeah, TLT's ACT could almost match the clinic lab % numbers in some cancer indications. NOT NMIBC, because the inexact delivery, the fragility and age of the patients, etc. Yet down the road I see no reason why better dosimetry, delivery, techniques, could be developed that would let Ruvidar shine. That won't help SP in the near term. I do expect NMIBC CR %'s to greatly improve over time, dbl from here?...

It will be interesting to see 450 day CR % numbers for solid tumors once TLT starts injecting GMB and NSCLS tumors and then zapping them with x-rays...  90s CR % maybe?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities